Conditional survival and excess mortality after high-dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway

Smeland, Knut Halvor Bjøro; Kiserud, Cecilie E.; Lauritzsen, Grete F.; Fagerli, Unn-Merete; Falk, Ragnhild Sørum; Fluge, Øystein; Fosså, Alexander; Kolstad, Arne; Loge, Jon Håvard; Maisenhölder, Martin; Kvaløy, Stein; Holte, Harald

doi:10.3324/haematol.2014.119214

Cited by 13 publications

(12 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We assessed the benefit of BV in the post-ASCT relapse situation by comparing patients treated with BV and a population-based historical cohort [20]. With no systematic differences in baseline characteristics, survival improved significantly.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Brentuximab vedotin in relapsed or refractory classical hodgkin lymphoma: real life experience in Norway 2011–2016

et al. 2019

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…Updates for surviving patients were collected last in March 2019. Patients treated with BV for a post-ASCT relapse were compared to 49 patients that underwent ASCT for r/r cHL between 1987 and 2008 and relapsed before 2011, all part of a recent national survey [20].…”

Section: Patientsmentioning

confidence: 99%

Brentuximab vedotin in relapsed or refractory classical hodgkin lymphoma: real life experience in Norway 2011–2016

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Conditional survival is a statistical method to estimate survival of a cohort under the condition that the group has already survived a certain period of time, producing more relevant information for cancer survivors than traditional survival estimates from time of HDT-ASCT. Conditional survival has previously been reported after HDT-ASCT for Hodgkin lymphoma (Smeland et al, 2015) and all haematological malignancies together (Vanderwalde et al, 2013). The latter single-centre study reported 5-year relative survival for all NHL together (n = 1028) of 62%, increasing to 82% and 87% conditional on having survived 5 and 10 years after HDT-ASCT, respectively (Vanderwalde et al, 2013).…”

mentioning

confidence: 89%

A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non‐Hodgkin lymphoma

et al. 2016

View full text Add to dashboard Cite

This national population-based study aimed to investigate conditional survival and standardized mortality ratios (SMR) after high-dose therapy with autologous stem-cell transplantation (HDT-ASCT) for non-Hodgkin lymphoma (NHL), and to analyse cause of death, relapses and second malignancies. All patients ≥18 years treated with HDT-ASCT for NHL in Norway between 1987 and 2008 were included (n = 578). Information from the Cause of Death Registry and Cancer Registry of Norway were linked with clinical data. The 5-, 10- and 20-year overall survival was 61% (95% confidence interval [CI] 56-64%), 52% (95%CI 48-56%) and 45% (95%CI 40-50%), respectively. The 5-year survival conditional on having survived 2, 5 and 10 years after HDT-ASCT was 81%, 86% and 93%. SMRs were 12·3 (95%CI 11·0-13·9), 4·9 (95%CI 4·1-5·9), 2·4 (95%CI 1·8-3·2) and 1·0 (95%CI 0·6-1·8) for the entire cohort and for patients having survived 2, 5 and 10 years after HDT-ASCT respectively. Of the 281 deaths observed, 77% were relapse-related. Treatment-related mortality was 3·6%. The 10-year cumulative incidence of second malignancies was 7·9% and standardized incidence ratio was 2·0 (95%CI 1·5-2·6). NHL patients treated with HDT-ASCT were at increased risk of second cancer and premature death. The mortality was still elevated at 5 years, but after 10 years mortality equalled that of the general population.

show abstract

“…The past three decades, high-dose chemotherapy with autologous stem cell transplantation (HDT-ASCT) has been a treatment option for relapsed or refractory Hodgkin (HL) and non-Hodgkin lymphomas (NHL), or as consolidation of first remission in selected patients with NHL with particularly high risk of relapse [1,2]. With improvements in diagnosis and treatment, the number of lymphoma survivors (LSs) post-HDT-ASCT has increased, and 5-year survival up to 73% and 62% have been reported for HL and NHL, respectively [3][4][5].…”

Section: Introductionmentioning

confidence: 99%

Obstructive and restrictive pulmonary dysfunction in long-term lymphoma survivors after high-dose therapy with autologous stem cell transplantation

et al. 2017

View full text Add to dashboard Cite

show abstract

Conditional survival and excess mortality after high-dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway

Cited by 13 publications

References 15 publications

Brentuximab vedotin in relapsed or refractory classical hodgkin lymphoma: real life experience in Norway 2011–2016

Brentuximab vedotin in relapsed or refractory classical hodgkin lymphoma: real life experience in Norway 2011–2016

A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non‐Hodgkin lymphoma

Obstructive and restrictive pulmonary dysfunction in long-term lymphoma survivors after high-dose therapy with autologous stem cell transplantation

Contact Info

Product

Resources

About